Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region

Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010

Chi Chang Huang, Yao Shen Chen, Han Siong Toh, Yu Lin Lee, Yuag Meng Liu, Cheng Mao Ho, Po Liang Lu, Chun Eng Liu, Yen Hsu Chen, Jen Hsien Wang, Hung Jen Tang, Kwok Woon Yu, Yung Ching Liu, Yin Ching Chuang, Yingchun Xu, Yuxing Ni, Wen Chien Ko, Po Ren Hsueh

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This study examined the rates of susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates that had been obtained from patients with intraabdominal infections in the Asia-Pacific region as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Susceptibility profiles obtained using 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints were compared with those obtained using the 2011 CLSI breakpoints. From 2002 to 2010, Escherichia coli and Klebsiella pneumoniae together accounted for more than 60 of the 13714 Enterobacteriaceae isolates analyzed during the study period. Extended-spectrum β-lactamase (ESBL) producers comprised 28.2 of E. coli isolates and 22.1 of K. pneumoniae isolates in the Asia-Pacific region, with China (55.6 and 33.7, respectively) and Thailand (43.1 and 40.7, respectively) having the highest proportions of ESBL producers. Based on the 2011 CLSI criteria, 77.2 of the Enterobacteriaceae isolates, 40.4 of ESBL-producing E. coli, and 25.2 of ESBL-producing K. pneumoniae isolates were susceptible to ceftazidime. Carbapenems showed in vitro activity against >90 of Enterobacteriaceae isolates in all participating countries, except for ertapenem in South Korea (susceptibility rate 82.2). Marked differences (>5) in susceptibility of ESBL-producing E. coli and K. pneumoniae isolates to carbapenems were noted between the profiles obtained using the 2009 CLSI criteria and those using the 2011 CLSI criteria. Continuous monitoring of antimicrobial resistance is necessary in the Asia-Pacific region.

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Carbapenems
Enterobacteriaceae
Cephalosporins
Klebsiella pneumoniae
Escherichia coli
Intraabdominal Infections
Republic of Korea
Ceftazidime
Thailand
China

Keywords

  • Carbapenems
  • Cephalosporins
  • Enterobacteriaceae
  • Extended-spectrum β-lactamase
  • Intra-abdominal infections

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region : Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. / Huang, Chi Chang; Chen, Yao Shen; Toh, Han Siong; Lee, Yu Lin; Liu, Yuag Meng; Ho, Cheng Mao; Lu, Po Liang; Liu, Chun Eng; Chen, Yen Hsu; Wang, Jen Hsien; Tang, Hung Jen; Yu, Kwok Woon; Liu, Yung Ching; Chuang, Yin Ching; Xu, Yingchun; Ni, Yuxing; Ko, Wen Chien; Hsueh, Po Ren.

In: International Journal of Antimicrobial Agents, Vol. 40, No. SUPPL. 1, 06.2012.

Research output: Contribution to journalArticle

Huang, Chi Chang ; Chen, Yao Shen ; Toh, Han Siong ; Lee, Yu Lin ; Liu, Yuag Meng ; Ho, Cheng Mao ; Lu, Po Liang ; Liu, Chun Eng ; Chen, Yen Hsu ; Wang, Jen Hsien ; Tang, Hung Jen ; Yu, Kwok Woon ; Liu, Yung Ching ; Chuang, Yin Ching ; Xu, Yingchun ; Ni, Yuxing ; Ko, Wen Chien ; Hsueh, Po Ren. / Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region : Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. In: International Journal of Antimicrobial Agents. 2012 ; Vol. 40, No. SUPPL. 1.
@article{1c06f58710fb48f9aead3d41d4330557,
title = "Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010",
abstract = "This study examined the rates of susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates that had been obtained from patients with intraabdominal infections in the Asia-Pacific region as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Susceptibility profiles obtained using 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints were compared with those obtained using the 2011 CLSI breakpoints. From 2002 to 2010, Escherichia coli and Klebsiella pneumoniae together accounted for more than 60 of the 13714 Enterobacteriaceae isolates analyzed during the study period. Extended-spectrum β-lactamase (ESBL) producers comprised 28.2 of E. coli isolates and 22.1 of K. pneumoniae isolates in the Asia-Pacific region, with China (55.6 and 33.7, respectively) and Thailand (43.1 and 40.7, respectively) having the highest proportions of ESBL producers. Based on the 2011 CLSI criteria, 77.2 of the Enterobacteriaceae isolates, 40.4 of ESBL-producing E. coli, and 25.2 of ESBL-producing K. pneumoniae isolates were susceptible to ceftazidime. Carbapenems showed in vitro activity against >90 of Enterobacteriaceae isolates in all participating countries, except for ertapenem in South Korea (susceptibility rate 82.2). Marked differences (>5) in susceptibility of ESBL-producing E. coli and K. pneumoniae isolates to carbapenems were noted between the profiles obtained using the 2009 CLSI criteria and those using the 2011 CLSI criteria. Continuous monitoring of antimicrobial resistance is necessary in the Asia-Pacific region.",
keywords = "Carbapenems, Cephalosporins, Enterobacteriaceae, Extended-spectrum β-lactamase, Intra-abdominal infections",
author = "Huang, {Chi Chang} and Chen, {Yao Shen} and Toh, {Han Siong} and Lee, {Yu Lin} and Liu, {Yuag Meng} and Ho, {Cheng Mao} and Lu, {Po Liang} and Liu, {Chun Eng} and Chen, {Yen Hsu} and Wang, {Jen Hsien} and Tang, {Hung Jen} and Yu, {Kwok Woon} and Liu, {Yung Ching} and Chuang, {Yin Ching} and Yingchun Xu and Yuxing Ni and Ko, {Wen Chien} and Hsueh, {Po Ren}",
year = "2012",
month = "6",
doi = "10.1016/S0924-8579(12)70003-1",
language = "English",
volume = "40",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region

T2 - Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010

AU - Huang, Chi Chang

AU - Chen, Yao Shen

AU - Toh, Han Siong

AU - Lee, Yu Lin

AU - Liu, Yuag Meng

AU - Ho, Cheng Mao

AU - Lu, Po Liang

AU - Liu, Chun Eng

AU - Chen, Yen Hsu

AU - Wang, Jen Hsien

AU - Tang, Hung Jen

AU - Yu, Kwok Woon

AU - Liu, Yung Ching

AU - Chuang, Yin Ching

AU - Xu, Yingchun

AU - Ni, Yuxing

AU - Ko, Wen Chien

AU - Hsueh, Po Ren

PY - 2012/6

Y1 - 2012/6

N2 - This study examined the rates of susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates that had been obtained from patients with intraabdominal infections in the Asia-Pacific region as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Susceptibility profiles obtained using 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints were compared with those obtained using the 2011 CLSI breakpoints. From 2002 to 2010, Escherichia coli and Klebsiella pneumoniae together accounted for more than 60 of the 13714 Enterobacteriaceae isolates analyzed during the study period. Extended-spectrum β-lactamase (ESBL) producers comprised 28.2 of E. coli isolates and 22.1 of K. pneumoniae isolates in the Asia-Pacific region, with China (55.6 and 33.7, respectively) and Thailand (43.1 and 40.7, respectively) having the highest proportions of ESBL producers. Based on the 2011 CLSI criteria, 77.2 of the Enterobacteriaceae isolates, 40.4 of ESBL-producing E. coli, and 25.2 of ESBL-producing K. pneumoniae isolates were susceptible to ceftazidime. Carbapenems showed in vitro activity against >90 of Enterobacteriaceae isolates in all participating countries, except for ertapenem in South Korea (susceptibility rate 82.2). Marked differences (>5) in susceptibility of ESBL-producing E. coli and K. pneumoniae isolates to carbapenems were noted between the profiles obtained using the 2009 CLSI criteria and those using the 2011 CLSI criteria. Continuous monitoring of antimicrobial resistance is necessary in the Asia-Pacific region.

AB - This study examined the rates of susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates that had been obtained from patients with intraabdominal infections in the Asia-Pacific region as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Susceptibility profiles obtained using 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints were compared with those obtained using the 2011 CLSI breakpoints. From 2002 to 2010, Escherichia coli and Klebsiella pneumoniae together accounted for more than 60 of the 13714 Enterobacteriaceae isolates analyzed during the study period. Extended-spectrum β-lactamase (ESBL) producers comprised 28.2 of E. coli isolates and 22.1 of K. pneumoniae isolates in the Asia-Pacific region, with China (55.6 and 33.7, respectively) and Thailand (43.1 and 40.7, respectively) having the highest proportions of ESBL producers. Based on the 2011 CLSI criteria, 77.2 of the Enterobacteriaceae isolates, 40.4 of ESBL-producing E. coli, and 25.2 of ESBL-producing K. pneumoniae isolates were susceptible to ceftazidime. Carbapenems showed in vitro activity against >90 of Enterobacteriaceae isolates in all participating countries, except for ertapenem in South Korea (susceptibility rate 82.2). Marked differences (>5) in susceptibility of ESBL-producing E. coli and K. pneumoniae isolates to carbapenems were noted between the profiles obtained using the 2009 CLSI criteria and those using the 2011 CLSI criteria. Continuous monitoring of antimicrobial resistance is necessary in the Asia-Pacific region.

KW - Carbapenems

KW - Cephalosporins

KW - Enterobacteriaceae

KW - Extended-spectrum β-lactamase

KW - Intra-abdominal infections

UR - http://www.scopus.com/inward/record.url?scp=84863446793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863446793&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(12)70003-1

DO - 10.1016/S0924-8579(12)70003-1

M3 - Article

VL - 40

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - SUPPL. 1

ER -